SAN FRANCISCO–(BUSINESS WIRE)–Sonder Holdings Inc. (NASDAQ: SOND; the “Company” or “Sonder”), a leading next-generation hospitality company…
Categoría: Business Wire
Category Added in a WPeMatico Campaign
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
— First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000…
Khan World School at ASU Prep Accelerates Expansion Thanks to Exceptional Academic Performance by Pilot Cohort
Online Honors Program Enrolling Students in Grades 6-12 for 2023-24 School Year TEMPE, Ariz.–(BUSINESS WIRE)–Building on…
BlueRiver Acquisition Corp. to Transfer Listing To NYSE American
NEW YORK–(BUSINESS WIRE)–BlueRiver Acquisition Corp. (NYSE: BLUA) (“BlueRiver”), announced today that it intends to transfer its…
NUTANIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Nutanix, Inc. on Behalf of Nutanix Stockholders and Encourages Investors to Contact the Firm
NEW YORK–(BUSINESS WIRE)–#A–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating…
OPENDOOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Opendoor Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK–(BUSINESS WIRE)–#A–Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating…
Eutelsat and Intelsat Sign Multi-Orbit Contract Enhancing Connectivity with OneWeb Services
Ground-breaking blend of multi-orbit assets providing unmatched connectivity service for air, land and sea customers where…
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
QIAGEN to develop PCR test to detect isocitrate dehydrogenase-1 (IDH1) mutations in AML patients to be…
Nidec’s Disaster Relief and Recovery Assistance for Turkey-Syria Earthquake
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (“Nidec”) would like to extend its deepest…
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
Pooled analysis of safety data from 5 clinical studies in 189 patients constituting the largest ever…